Amyotrophic lateral sclerosis

(ALS, Charcot, Lou Gehrig)

Psychopharmacology logo

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

Main results: Cannabis containing equivalent concentrations of CBD and THC appears no less impairing than THC-dominant cannabis, and in some ...
Read more…
Drug Testing and Analysis logo

Orally administered cannabidiol (CBD) does not produce false‐positive tests for THC on the Securetec DrugWipe® 5S or Dräger Drug Test® 5000

Main results: Orally administered CBD does not appear to produce false-positive (or true-positive) tests for THC on the DW-5S and ...
Read more…
Accident Analysis & Prevention logo

Simulated driving performance among daily and occasional cannabis users

Main results: Occasional users had a similar drug effect as daily users but lower blood THC. Smoked cannabis led to ...
Read more…
Neuroscience & Biobehavioral Reviews logo

Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review

Main results: Most driving-related skills are predicted to recover within ∼5-hs (and almost all within ∼7-hs) of inhaling 20 mg Δ9-THC ...
Read more…
Frontiers in Pharmacology logo

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

Main results: we highlight the possibility that, in addition to neurons, glial changes could help to explain the complex pharmacology ...
Read more…
Pharmacology Research & Perspectives logo

Diversity of molecular targets and signaling pathways for CBD

Main results: CBD’s potential as a therapeutic comes from its multiple mechanisms of action. This wide range of pharmacological activity ...
Read more…
BMC Neurology logo

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

Main results: THC:CBD may serve as an important addition to the spectrum of treatment options of spasticity in ALS.*Posology used: ...
Read more…
Frontiers in neurology logo

Spasticity mechanisms – for the clinician

Main results: It is highly likely that in humans, reduction of spinal inhibitory mechanisms (in particular that of disynaptic reciprocal ...
Read more…
British Journal of Clinical Pharmacology

The pharmacokinetics and the pharmacodynamics of cannabinoids

Main results: prescribing cannabis medicines using a ʻstart low and go slowʼ approach, carefully observing the patient for desired and ...
Read more…
CMAJ logo

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Main results: Smoked cannabis was superior to placebo in symptom and pain reduction in participants with treatment-resistant spasticity.*Posology used: an ...
Read more…